---
title: "New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293757164.md"
description: "Jersey City, New Jersey - Organon has recently unveiled an analysis of Phase 3 pooled data for VTAMA (tapinarof) cream, 1%, demonstrating early and consistent improvements in eczema patients across various age groups. This analysis presents promising results for the medication, showcasing its effectiveness in treating eczema. This is a significant development in the field of dermatology, highlighting the potential of VTAMA cream in providing relief to individuals suffering from eczema."
datetime: "2026-07-24T12:08:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293757164.md)
  - [en](https://longbridge.com/en/news/293757164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293757164.md)
---

# New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

Jersey City, New Jersey - Organon has recently unveiled an analysis of Phase 3 pooled data for VTAMA (tapinarof) cream, 1%, demonstrating early and consistent improvements in eczema patients across various age groups. This analysis presents promising results for the medication, showcasing its effectiveness in treating eczema. This is a significant development in the field of dermatology, highlighting the potential of VTAMA cream in providing relief to individuals suffering from eczema.

### Related Stocks

- [OGN.US](https://longbridge.com/en/quote/OGN.US.md)

## Related News & Research

- [Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary](https://longbridge.com/en/news/294511535.md)
- [Organon Announces Quarterly Dividend | OGN Stock News](https://longbridge.com/en/news/294516961.md)
- [Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+](https://longbridge.com/en/news/293807164.md)
- [B Capital invests in pediatric behavioral health provider Flourish Health](https://longbridge.com/en/news/294365281.md)
- [Stocks in Play: Bausch Health Companies Inc.](https://longbridge.com/en/news/294078973.md)